Abstract
Background: Some but not all previous studies report that pneumonia in children aged less than five years is associated with lower lung function and elevated risk of respiratory disease. To date, none have explored these associations in at-risk populations such as First Nations Australians, whose incidence of early childhood pneumonia is among the highest reported in the world. Methods: This cross-sectional study included 1276 First Nations Australian children/young adults aged 5–25 years recruited from regional/remote Queensland and Northern Territory communities and schools. Associations between pneumonia and both spirometry values and asthma were investigated using linear and logistic regression. Results: Early childhood pneumonia was associated with lower FEV1 and FVC Z-scores, but not FEV1/FVC% Z-scores, when occurring before age three (FEV1 β = −0.42, [95%CI −0.79, −0.04]; FVC β = −0.62, [95%CI −1.14, −0.09]), and between three and five years (β = −0.50, [95%CI −0.88, −0.12]; β = −0.63, [95%CI −1.17, −0.10]), compared to those who never had pneumonia. Similarly, pneumonia occurring when aged before age three years (OR = 3.68, 95%CI 1.96–6.93) and three to five years (OR = 4.81, 95%CI 1.46–15.8) was associated with increased risk of asthma in later childhood. Conclusions: Early childhood pneumonia is associated with lung function deficits and increased asthma risk in later childhood/early adulthood in First Nations Australians. The disproportionate impact of pneumonia on at-risk children must be addressed as a priority.
Original language | English |
---|---|
Article number | 5727 |
Pages (from-to) | 1-11 |
Number of pages | 11 |
Journal | Journal of Clinical Medicine |
Volume | 10 |
Issue number | 24 |
DOIs | |
Publication status | Published - 1 Dec 2021 |
Bibliographical note
The authors received no specific funding for this work. AJC is supported by a NationalHealth and Medical Research Council (NHMRC) Postgraduate Scholarship (APP2003334). JMM
is supported by a Children’s Hospital Foundation fellowship (RPC0772019). ABC is supported
by a NHMRC Senior Practitioner Fellowship (APP1154302) and Children’s Hospital Foundation
(top-up #50286) and reports multiple grants from NHMRC and other fees to the institution from work
relating to IDMC membership of an unlicensed vaccine (GSK), and a COVID-19 vaccine (Moderna)
outside the submitted work. DV is supported by a fellowship from the NHMRC Centre of Research
Excellence for bronchiectasis in children (APP1170958). MSM reports other grants from Children’s
Hospital Foundation. SCD is supported by a NHMRC Leader Investigatorship (APP1193993).
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.